Table 1.
Baseline characteristics of patients*
| Characteristics | Neoadjuvant chemotherapy with S-1 (N = 106) | Up-front surgery (N = 54) | P |
|---|---|---|---|
| Age - yr | 61±13 | 56±16 | 0.08 |
| Female sex - no. (%) | 41 (38.7) | 20 (34.5) | 0.9 |
| Primary tumor site | 0.4 | ||
| Tongue | 69 (65.0) | 38 (70.3) | |
| Gingiva | 19 (17.9) | 6 (11.1) | |
| Floor | 5 (4.7) | 5 (9.2) | |
| Other | 13 (12.2) | 5 (9.2) | |
| Clinical T stage - no. (%) | 0.2 | ||
| T1 | 33 (31.1) | 17 (31.5) | |
| T2 | 60 (56.6) | 35 (64.8) | |
| T3 | 13 (12.2) | 2 (3.7) | |
| Clinical N stage - no. (%) | 0.7 | ||
| N0 | 97 (91.5) | 51 (94.5) | |
| N1 | 9 (8.5) | 3 (5.5) | |
| AJCC clinical stage - no. (%) | 0.1 | ||
| I | 33 (31.1) | 17 (31.5) | |
| II | 53 (50.0) | 33 (61.1) | |
| III | 20 (18.9) | 4 (7.4) | |
| Histological differentiation - no. (%) | 0.2 | ||
| Well | 66 (62.3) | 35 (64.8) | |
| Well to moderately | 19 (17.9) | 4 (7.4) | |
| Moderately | 12 (11.3) | 12 (22.2) | |
| Poorly to moderately | 3 (2.8) | 1 (1.9) | |
| Poorly | 1 (1.0) | 1 (1.9) | |
| Unknown | 5 (4.7) | 1 (1.9) | |
| Body mass index$ | 22±3 | 22±4 | 0.9 |
| Adjuvant chemotherapy - no. (%) | 36 (34.0) | 11 (20.4) | 0.1 |
AJCC, American Joint Committee on Cancer.
*
Plus-minus values are means ± SD. Percentages may not total 100 because of rounding.
$
Data were available for 106 patients in the chemotherapy group and 53 in the surgery group.